Deconvolution of Buparlisib's mechanism of action defines specific PI3K and tubulin inhibitors for therapeutic intervention.
Bohnacker, T., Prota, A.E., Beaufils, F., Burke, J.E., Melone, A., Inglis, A.J., Rageot, D., Sele, A.M., Cmiljanovic, V., Cmiljanovic, N., Bargsten, K., Aher, A., Akhmanova, A., Diaz, J.F., Fabbro, D., Zvelebil, M., Williams, R.L., Steinmetz, M.O., Wymann, M.P.(2017) Nat Commun 8: 14683-14683
- PubMed: 28276440 
- DOI: 10.1038/ncomms14683
- Primary Citation of Related Structures:  
5M8D, 5M8G, 5JHB, 5JHA, 5M7G, 5M7E - PubMed Abstract: 
BKM120 (Buparlisib) is one of the most advanced phosphoinositide 3-kinase (PI3K) inhibitors for the treatment of cancer, but it interferes as an off-target effect with microtubule polymerization. Here, we developed two chemical derivatives that differ fr ...